Delivery Order SPE2DB24D1205-SPE2DB25FDAKV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets in a quantity of 30 units, with a contract ceiling value of $10,662.57. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for completion by September 30, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $10,662.57. The order is scheduled for completion by September 2, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency awarded a $58,164.68 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this order supports the...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of Tagrisso 40 mg tablets (30-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy used in treating certain lung cancers,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $31,987.71. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating that AmerisourceBergen Drug Corp...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $53,312.85 under a firm fixed-price contract type. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a competitively awarded, non-set-aside order fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages) with a ceiling value of $21.3K. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is scheduled for completion by October 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDAKVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain types of lung cancer, reflecting the Defense Logistics Agency's ongoing pharmaceutical procurement needs for military and veteran healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen has demonstrated consistent capability to fulfill competitive federal medical supply requirements across a diverse portfolio of therapeutic domains, including specialty medications, branded and generic pharmaceuticals, and medical supplies supporting military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 9/12/25 |